Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech

Streetwise Reports, Streetwise Reports
0 Comments| May 2, 2019

{{labelSign}}  Favorites

Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report.

Click to enlarge

In an April 29 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Forty Seven Inc. (FTSV:NASDAQ) agreed to expand its collaborative efforts with Genentech to now include a third clinical trial.

This latest study will evaluate Forty Seven's lead product 5F9 in combination with Genentech's rituximab and atezolizumab in patients with diffuse large B-cell lymphoma (DLBCL). "We believe the new triplet study could help provide additional confidence in the safety and efficacy of 5F9," Ramakanth commented.

The analyst noted that the purpose of the triple combination study is likely to build upon the "promising results" from a previous combination Phase 1b study of 5F9 with rituximab in DLBCL patients, noted Ramakanth.

On its own, Forty Seven is continuing to evaluate that very double regimen in its Phase 2 study in patients with DLBCL and follicular lymphoma. The company is expected to release results from that trial in Q2/19.

Ramakanth indicated that Forty Seven also should provide two other clinical updates this year. One, slated for delivery in Q2/19, is on its Phase 1b study, in which 5F9 is being evaluated as both a monotherapy and in combination with azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

The second update, due out in Q4/19, is on two Phase 1b studies, one that is testing 5F9 with avelumab (Bavencio) in ovarian cancer patients and the other which is evaluating 5F9 with cetuximab in colorectal cancer patients.

H.C. Wainwright has a Buy rating and a $21 per share price target on Forty Seven, whose stock is currently trading at around $18.26 per share.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from H.C. Wainwright & Co., Forty Seven Inc., First Take, April 29, 2019

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Swayampakula Ramakanth, Ph.D., Sean Lee and Sean Kang, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Forty Seven, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of March 31, 2019 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Forty Seven, Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Forty Seven, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in Forty Seven, Inc. as of the date of this research report.

{{labelSign}}  Favorites


No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media


Featured Company